Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moENTACAPONE (entacapone) by Aurobindo Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for parkinson's disease (see ), parkinson's disease. First approved in 2015.
Drug data last refreshed 20h ago
Catechol O-Methyltransferase Inhibitors
Catechol-O-Methyltransferase Inhibitor
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
Pilot Study of Entacapone for Methamphetamine Abuse
Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
Worked on ENTACAPONE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo